Nasdaq

FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome

EMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug ...
Stockhouse

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

In the United States, FINTEPLA is available only through a restricted distribution program called the FINTEPLA REMS program. FINTEPLA is available in Europe under a controlled access program requested ...
BioWorld

Zogenix’s Fintepla approved by FDA to treat seizures in children

The FDA has approved Zogenix Inc.’s Fintepla (fenfluramine), an oral treatment for patients age 2 and older with seizures associated with Dravet syndrome, a rare, pediatric-onset form of epilepsy. The ...
PharmiWeb

Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution

FINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with Dravet syndrome in patients aged two years and older. The new program supports ...